● Recruiting

CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

Condition: HER2-negative Breast Cancer · Metastatic Breast Cancer · Sponsor: University of Texas Southwestern Medical Center

PhasePhase 1

Planned participants30

Who can joinAll sexes, 18 Years to 99 Years

Healthy volunteersNo

About this study

This research study is being done to find out if the immunotherapy drugs called CDX-301 and CDX-1140 in combination with the standard chemotherapy treatment pegylated liposomal doxorubicin (PLD, Doxil) are safe and effective at controlling the cancer in patients with metastatic triple Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer, and to determine a safe dose and treatment schedule of the three drugs. This research study will also test how your immune system responds to these treatments alone and in combination.

This description comes directly from the study's public registry record.

Talk to the study team

Meredith Carter, MS · (214) 648-7020 · Meredith.carter@utsouthwestern.edu

Always discuss trial participation with your own doctor first.

Locations (7)

University of Chicago Comprehensive Cancer Center	Chicago, Illinois, United States	Recruiting
Johns Hopkins University	Baltimore, Maryland, United States	Recruiting
University of North Carolina	Chapel Hill, North Carolina, United States	Recruiting
Sarah Cannon Research Institute	Nashville, Tennessee, United States	Withdrawn
Texas Oncology, P.A.	Dallas, Texas, United States	Active Not Recruiting
UT Southwestern Medical Center	Dallas, Texas, United States	Recruiting
The University of Texas Health Science Center at San Antonio	San Antonio, Texas, United States	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05029999